Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Goldman Sachs Analyst Maintains Neutral Rating on Cricut with Lowered Price Target

Elaine Mendonca by Elaine Mendonca
March 6, 2024
in Breaking News
0
Finance_ Charts for stock trading
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

On March 6, 2024, analyst Eric Sheridan from Goldman Sachs reiterated a Neutral rating on Cricut (NASDAQ: CRCT) while reducing the price target to $5.75 from $7. Sheridan’s decision to lower the price target was influenced by a careful assessment of Cricut’s growth opportunities and the challenges posed by economic conditions. Despite the revised price target, Sheridan’s overall perspective on Cricut remains unchanged, maintaining a Neutral stance on the company.

CRCT Stock Performance Declines Significantly on March 6, 2024: What Investors Need to Know

On March 6, 2024, CRCT, a real estate investment trust, experienced a significant decline in its stock performance. According to data from CNN Money, the stock is currently trading near the bottom of its 52-week range and below its 200-day simple moving average. This indicates that CRCT has been struggling to maintain positive momentum in the market.

The price of CRCT shares dropped by $0.25 since the market last closed, representing a 5.18% decrease in value. The stock opened at $4.65 on March 6th, which was $0.18 lower than its previous close. This lower opening price suggests that investors were hesitant to buy CRCT shares at the previous day’s closing price.

The decline in CRCT’s stock performance on March 6th may be attributed to various factors, such as overall market conditions, industry trends, or company-specific news. Investors should closely monitor CRCT’s performance in the coming days to assess whether this downward trend will continue or if there will be a potential rebound in the stock price.

It is important for investors to conduct thorough research and analysis before making any investment decisions, especially in volatile market conditions. CRCT’s current position near the bottom of its 52-week range and below its 200-day simple moving average should serve as a cautionary signal for investors to proceed with caution when considering investing in this stock.

CRCT Stock Analysis: Decline in Total Revenue and Net Income, But Positive Momentum in Q3

On March 6, 2024, CRCT stock experienced mixed performances based on the latest financial data provided by CNN Money. The company’s total revenue for the past year was $886.30 million, which decreased by 32.15% compared to the previous year. However, the total revenue remained flat since the last quarter, with a reported revenue of $174.91 million for Q3.

Similarly, CRCT’s net income for the past year was $60.67 million, reflecting a decrease of 56.81% since the previous year. On a positive note, the net income increased by 7.5% since the last quarter, reaching $17.23 million for Q3.

Earnings per share (EPS) for CRCT stood at $0.28 for the past year, representing a 56.56% decrease compared to the previous year. However, the EPS increased by 7.13% since the last quarter, reaching $0.08 for Q3.

Overall, CRCT’s financial performance on March 6, 2024, showed a decline in total revenue and net income compared to the previous year. However, there was a slight improvement in net income and EPS since the last quarter, indicating some positive momentum for the company. Investors may want to closely monitor CRCT’s future financial reports to assess the company’s growth trajectory and investment potential.

Tags: CRCT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Analysts Divided on First Watch Restaurant Groups Future

MA stock news

Bitcoin Resurgence Sparks Rise in Cryptocurrency Stocks

Finances

Financial Institutions Bullish on Carvana Options Trading Activity and Sentiments Analyzed

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com